Oncorus to Host Investor Day Featuring its IV-Administered Synthetic Viral RNA (vRNA) Immunotherapy Platform and Lead Synthetic vRNA Product Candidates

Ads

You May Also Like

Immuron Announces A$5.1M Private Placement to U.S. Fund

MELBOURNE, Australia, March 13, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian ...

Aptevo Therapeutics Augments Leadership Team

Appoints Former GlaxoSmithKline Executive Randy Maddux Senior Vice President, Operations Jane Gross, Ph.D., Promoted to ...